April 2025 in “Acta Dermato Venereologica” Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
73 citations
,
April 2017 in “Scientific Reports” Nitrogen starvation in microalgae increases lipid production, making it a potential biofuel source.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
12 citations
,
January 2018 in “Breast Cancer Basic and Clinical Research” Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.
6 citations
,
March 2012 in “Journal of Accounting Education” Regal Hair Salon records gift card sales as liabilities and recognizes revenue when redeemed.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
5 citations
,
August 2018 in “Neurology and Therapy” Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
3 citations
,
April 2024 in “International Journal of Women’s Dermatology” Access to JAK inhibitor therapy for alopecia areata patients is difficult, especially for racial minorities.
3 citations
,
March 2023 in “ACTA SCIENTIAE VETERINARIAE” Real-time PCR quickly and accurately detects ringworm in dogs.
2 citations
,
February 2025 in “Allergies” Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
1 citations
,
July 2023 in “Cureus” Cetosomal minoxidil alone and with finasteride is effective and well-tolerated for hair loss treatment.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
November 2025 in “Frontiers in Pharmacology” 64 drugs can cause hair loss, needing better monitoring and updated labels.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
October 2025 in “Clinical and Experimental Dermatology” Low-dose oral minoxidil significantly improves hair density in non-scarring alopecia.
September 2025 in “Journal of Dermatology Research” Sebamed® shampoo effectively reduces hair loss and promotes hair growth.
August 2025 in “Clinical and Experimental Dermatology” Alopecia areata treatments often don't lead to lasting improvement.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
May 2025 in “Journal of Cosmetic Dermatology” Cuticapil Stem Hair Serum improves hair growth and reduces shedding when added to minoxidil.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
February 2025 in “Plastic and Aesthetic Research” Minoxidil and finasteride effectively promote hair regrowth within 3 months.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Clascoterone cream effectively reduces acne severity and is safe for patients 12 and older.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.